mufa 14:1 c

MUFA 14:1 c, commonly known as myristoleic acid or cis‑9‑tetradecenoic acid, is a monounsaturated fatty acid (MUFA) with a 14‑carbon chain and a single cis double bond at the ninth carbon position (omega‑5 or n‑5 configuration). In the nomenclature C14:1 n‑5, '14' refers to the number of carbon atoms, '1' indicates one double bond, and 'n‑5' denotes the position of the double bond from the methyl end. This structural configuration places MUFA 14:1 c in the broader category of monounsaturated fats, which are fatty acids characterized by a single double bond and are generally liquid at room temperature but can solidify when chilled. MUFA 14:1 c is less abundant in nature compared to more common MUFAs such as oleic acid (C18:1) and palmitoleic acid (C16:1), but it is present in trace amounts in a variety of foods including animal fats, dairy fats, and some plant sources. Because the human body can synthesize MUFAs via desaturation of saturated fatty acids through enzymes like stearoyl‑CoA desaturase, myristoleic acid is not considered an essential nutrient with a defined dietary requirement. Instead, it contributes to the pool of MUFAs consumed and synthesized in the body. On a molecular level, MUFAs, including MUFA 14:1 c, play roles in cellular lipid membranes, contributing to membrane fluidity and function, and serve as energy sources when metabolized. The presence of the cis configuration influences the geometry of the fatty acid chain, causing a 'kink' that affects how these molecules pack into membranes and triglyceride structures. While the individual physiological roles of specific MUFAs like MUFA 14:1 c are not as comprehensively studied as those of major fatty acids like oleic acid, they form part of the overall dietary fat composition that nutrition science investigates for links to health outcomes such as lipid metabolism and inflammation. General nutrition guidelines emphasize the quality of dietary fats, recommending that diets include higher proportions of monounsaturated and polyunsaturated fats relative to saturated fats to support cardiovascular health and metabolic function.

MUFA 14:1 c participates in lipid metabolism as part of the broader class of monounsaturated fatty acids (MUFAs). MUFAs are key components of triglycerides and phospholipids in cell membranes, influencing membrane fluidity and cell signaling. While specific evidence on MUFA 14:1 c is limited, research on MUFAs generally shows that replacing saturated fats with MUFAs in the diet can improve intermediate markers linked to cardiovascular disease and type 2 diabetes. Systematic review evidence indicates that substituting saturated fats with MUFAs (including various MUFA species) is associated with improved blood lipid profiles, with reductions in LDL cholesterol and triglycerides and potential improvements in insulin responsiveness in both healthy and insulin‑resistant individuals. In addition to lipid modulation, diets higher in MUFAs are components of heart‑healthy dietary patterns such as the Mediterranean diet, which has been associated with lower risks of cardiovascular events. Although the causative role of individual MUFA species like MUFA 14:1 c is not independently established in large clinical trials, observational data and metabolic research suggest that overall MUFA intake contributes to metabolic health when it displaces less healthy fats. In mechanistic terms, MUFAs exhibit effects on lipid homeostasis via modulation of hepatic fatty acid oxidation and influencing gene expression related to lipid transport and storage. Moreover, MUFAs have been linked to anti‑inflammatory effects in some dietary contexts, contributing to reduced markers of inflammation when replacing saturated fats or refined carbohydrates. While studies have tended to focus on the more abundant MUFAs like oleic acid, MUFA 14:1 c may share structural and metabolic features characteristic of monounsaturated fats. Evidence from nutrition research underscores that the source of MUFAs matters; plant‑derived sources (e.g., olive oil, nuts) often come with additional beneficial nutrients such as antioxidants and phytochemicals, whereas animal fat sources can include higher proportions of saturated fats. Consequently, dietary guidance emphasizes quality dietary patterns rather than isolated fatty acid intake. Overall, while specific health benefit studies on MUFA 14:1 c are limited, the broader class of MUFAs has been linked to favorable effects on metabolic health and cardiovascular risk factors, particularly in the context of balanced dietary patterns.

Unlike essential nutrients such as vitamins and essential fatty acids (e.g., omega‑3 alpha‑linolenic acid), MUFA 14:1 c does not have an established Recommended Dietary Allowance (RDA) or Adequate Intake (AI) defined by authoritative bodies such as the NIH Office of Dietary Supplements or the Institute of Medicine. This is because the body can synthesize monounsaturated fatty acids from saturated fatty acid precursors via endogenous enzymatic pathways, and individual MUFA species like myristoleic acid are present in relatively low amounts in typical dietary patterns. Instead of prescribing a specific intake for MUFA 14:1 c, nutrition guidelines focus on the distribution of total dietary fats to support overall health. For example, national dietary guidelines recommend that total fat intake should account for about 20–35% of total daily caloric energy. Within this recommendation, a substantial proportion of fats should come from unsaturated fats (both monounsaturated and polyunsaturated), with limited intake of saturated fats to mitigate cardiovascular risk. While these guidelines do not delineate precise grams per day for MUFA 14:1 c, they support the intake of dietary patterns rich in healthy unsaturated fats, such as those found in plant oils and certain animal products. Therefore, individuals aiming to support metabolic health should prioritize foods containing predominantly MUFAs and PUFAs while keeping saturated fat intake within recommended limits. This approach naturally includes the consumption of a variety of monounsaturated fatty acids, including MUFA 14:1 c, as part of a balanced diet, although intake of this specific fatty acid may be small relative to more common MUFAs. For practical purposes, focusing on foods with high MUFA content — such as olive oil, nuts, avocados, and lean meats — contributes to a dietary pattern aligned with public health guidance for fat intake distribution.

There is no recognized clinical deficiency syndrome specific to MUFA 14:1 c, as this fatty acid is not classified as an essential nutrient. The human body can synthesize MUFAs endogenously through desaturation of saturated fatty acid precursors, so inadequate dietary intake of MUFA 14:1 c alone does not lead to a defined deficiency state. General signs of inadequate overall dietary fat intake — not specific to MUFA 14:1 c — may include poor absorption of fat‑soluble vitamins (A, D, E, K), dry skin, hormonal imbalances, and impaired energy metabolism, particularly when total fat intake is very low. However, these symptoms are associated with insufficient total fat rather than a deficit of a specific MUFA species. Because MUFAs form part of the broader lipid class that supports cellular membrane integrity and energy storage, extremely low intakes of unsaturated fats may theoretically affect membrane composition and lipid signaling pathways, but there is no specific clinical diagnostic criterion for MUFA 14:1 c deficiency. In clinical practice, assessment of fatty acid status often focuses on essential fatty acids (omega‑3 and omega‑6) because these cannot be synthesized by the body and have established requirement thresholds. Populations with very low total fat intake or with malabsorption conditions (e.g., cystic fibrosis, cholestatic liver disease, certain gastrointestinal disorders) may show signs of poor fat utilization, but these manifestations are not attributable to MUFA 14:1 c specifically. Therefore, ensuring a balanced intake of total fats — including MUFAs from a variety of food sources — is more relevant to dietary adequacy than focusing on individual fatty acids like MUFA 14:1 c.

Because MUFA 14:1 c is relatively uncommon, foods rich in this specific fatty acid tend to be those with mixed fat profiles, particularly animal fats and processed meat products. According to nutrient ranking data, top sources include fast‑food hamburger and cheeseburger patties and other beef products, where myristoleic acid content can reach several tenths of a gram per serving. Dairy products such as heavy whipping cream and cheeses (e.g., ricotta) also contain measurable amounts of MUFA 14:1 c. Beyond animal sources, plant foods such as peanuts, roasted or in oil, and some spices (e.g., turmeric, rosemary) contain small amounts of myristoleic acid, typically in the milligram range per 100 grams. Because MUFAs overall are abundant in a wide variety of foods, including olive oil, avocados, nuts, and seeds, including these foods in the diet supports overall monounsaturated fat intake. However, the proportion of MUFA 14:1 c specifically in these foods is low compared to more abundant MUFAs such as oleic and palmitoleic acids. When selecting foods for MUFA intake, prioritizing nutrient‑dense sources such as nuts, seeds, and high‑quality oils provides broader health benefits beyond individual fatty acid composition. It's also important to balance total fat intake within dietary goals and to limit processed foods high in saturated fats and added calories. By incorporating a variety of whole foods rich in unsaturated fats, individuals can support metabolic health while also obtaining a spectrum of fatty acids that contribute to lipid metabolism and cell function.

Monounsaturated fatty acids, including MUFA 14:1 c, are absorbed in the small intestine following digestion of triglycerides by pancreatic lipases. In the intestinal lumen, fats are emulsified by bile salts, hydrolyzed into free fatty acids and monoglycerides, and incorporated into micelles. These micelles facilitate passive diffusion of fatty acids across the enterocyte membrane. Once inside enterocytes, free fatty acids and monoglycerides are repackaged into triglycerides and assembled into chylomicrons, which enter the lymphatic system and then the bloodstream for distribution to tissues. Because MUFA 14:1 c is a component of dietary fats, its absorption follows the same pathways as other MUFAs. The efficiency of fatty acid absorption can be influenced by factors such as the overall fat content of the meal, the presence of bile salts, and gastrointestinal health. Dietary fats are generally well absorbed; however, conditions that impair bile production or pancreatic enzyme activity can reduce absorption efficiency. The presence of dietary fibers and phytosterols may also modestly reduce fat absorption by interfering with micelle formation. In terms of bioavailability, MUFAs do not require specific transporters for uptake into cells, but once in circulation, they are transported within lipoproteins. Tissue uptake is mediated by lipoprotein lipases and fatty acid transport proteins. Because MUFA 14:1 c is present in lower quantities compared to more common MUFAs, its specific metabolic handling may be proportionally limited, yet it contributes to the pool of circulating MUFAs following dietary intake. Overall, normal digestion and absorption mechanisms efficiently handle dietary MUFAs, and a balanced diet containing a mix of fats supports optimal lipid assimilation.

There are no established supplements that provide isolated MUFA 14:1 c, and there is no evidence supporting supplementation with myristoleic acid for health benefits. While some fatty acid supplements (e.g., fish oil, olive oil supplements) provide broader profiles of unsaturated fats, myristoleic acid is generally present in low amounts and not targeted in commercial products. Research on MUFA 14:1 c is limited, with studies largely focusing on its presence in foods and its role within the broader lipid context. Because the body can synthesize MUFAs endogenously and because MUFA 14:1 c is not considered essential, supplementation is not necessary for most people. Instead, individuals interested in the health benefits associated with unsaturated fats may consider dietary patterns that provide higher proportional intakes of MUFAs and PUFAs relative to saturated fats. When considering supplements that rich in unsaturated fats, choosing products with demonstrated quality, third‑party testing, and evidence of benefit (e.g., omega‑3 fish oil for cardiovascular and inflammatory support) is more appropriate than focusing on uncommon fatty acids without established requirements. Those with specific health conditions should consult healthcare providers before initiating any supplement regimen.

No specific toxicity or tolerable upper intake level (UL) has been defined for MUFA 14:1 c, and there are no reports of adverse effects from intake of this individual fatty acid at dietary levels. In general, consuming fats in balanced amounts consistent with dietary guidelines is considered safe for most individuals. Excessive intake of total fats, particularly from energy‑dense sources high in saturated and trans fats, can contribute to weight gain and elevated cardiovascular risk. However, consuming foods that contribute MUFAs, including MUFA 14:1 c in the context of overall unsaturated fat intake, does not have defined toxicity. Adverse outcomes associated with high fat consumption are largely linked to imbalanced dietary patterns rather than inherent toxicity of individual MUFAs.

Monounsaturated fatty acids are dietary components rather than pharmacological agents, and there are no well‑documented direct interactions between MUFA 14:1 c and medications. However, dietary fats can influence the absorption of certain fat‑soluble medications and nutrients. For example, high‑fat meals can increase the absorption of lipophilic drugs, potentially altering their pharmacokinetics, and may affect the timing or effectiveness of drugs that require fasting for optimal uptake. Additionally, diets high in unsaturated fats can influence lipid profiles and thus may interact with the effects of lipid‑lowering medications (e.g., statins) indirectly by affecting baseline cholesterol levels and metabolic parameters. Individuals on medications for lipid disorders or with conditions requiring specific dietary fat management should consult healthcare providers regarding dietary fat composition.

Common Forms: Not available as isolated supplement, Found in mixed fatty acid supplements (e.g., fish oil)

Typical Doses: No recommended supplemental dose

When to Take: Not applicable

Best Form: Not applicable; part of dietary triglycerides

⚠️ Interactions: No direct drug interactions documented